Detection of chromosomal abnormalities associated with breast cancer

• US 8,021,837 B2
• Filed: 02/24/2006
• Issued: 09/20/2011
• Est. Priority Date: 03/04/1992
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Sakamoto, Masaru, Pinkel, Daniel, Gray, Joe W, Kallioniemi, Ollie-Pekka, Kallioniemi, Anne, Waldman, Frederic
• Primary Examiner(s): Strzelecka; Teresa E
• Application Number:
  US11/361,316
• Publication Number:
  US 20060257895A1
• Time in Patent Office: 2,034 Days
• Field of Search: None
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6841 In situ hybridisation
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2537/157 A reaction step characterised by the number of molecules incorporated or released
• CPC Class Codes: C12Q 2545/114 involving a quantitation step
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G06F 15/025 adapted to a specific application
• CPC Class Codes: Y10S 436/813 Cancer

Abstract

Disclosed are new methods comprising the use of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread. Amplifications, duplications and/or deletions in the subject genome(s) can be detected. Also provided is a method of determining the absolute copy numbers of substantially all RNA or DNA sequences in subject cell(s) or cell population(s).

Claims

1. A method for detecting a copy number variation by detecting an amplification or gain of unique sequences at the chromosomal region of position q13 on chromosome 20 in a suspected breast cancer test sample from a subject, said method comprising:

(a) contacting a probe that binds selectively to a target polynucleotide sequence of said region with a nucleic acid sample prepared, directly or indirectly, from said test sample, wherein said nucleic acid sample comprises said target polynucleotide sequence and said probe is contacted with said sample under conditions in which said probe forms a stable hybridization complex with said target nucleic acid sequence; and

(b) detecting said hybridization complex to detect said amplification or gain of said chromosomal region.

2. The method of claim 1, wherein said probe is labeled.

3. The method of claim 1, wherein said nucleic acid sample is labeled.

4. The method of claim 1, wherein said nucleic acid sample comprises genomic DNA molecules.

5. The method of claim 1, wherein said nucleic acid sample comprises DNA amplified from said test sample.

6. The method of claim 1, wherein said nucleic acid sample comprises complementary DNA.

7. The method of claim 1, wherein the label is a fluorescent label.

8. The method of claim 7, wherein the labeled probe is detected using a fluorescence detector.

9. The method of claim 1, wherein an amplification or gain of unique sequences at the chromosomal region on chromosome 20, position q13 is detected, and said method additionally comprises treating said subject for breast cancer.